Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141:1954–70.

Article  CAS  PubMed  Google Scholar 

Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29:2126–33.

Article  PubMed  Google Scholar 

Kröger N, Wolschke C, Gagelmann N. How I treat transplant-eligible patients with myelofibrosis. Blood. 2023;142:1683–96.

Article  PubMed  Google Scholar 

Robin M, Wreede LC, de, Wolschke C, Schetelig J, Eikema D-J, van Lint MT, et al. Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2019;104:1782–8.

Article  PubMed  PubMed Central  Google Scholar 

Stern M, Wreede LC, de, Brand R, van Biezen A, Dreger P, Mohty M, et al. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia. 2014;28:2235–40.

Article  CAS  PubMed  Google Scholar 

Gagelmann N, Ayuk F, Wolschke C, Kröger N. Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis. Biol Blood Marrow Transpl. 2017;23:2184–91.

Article  CAS  Google Scholar 

Dybko J, Giordano U, Pilch J, Mizera J, Borkowski A, Mordak-Domagała M. Comparison of different rabbit anti-thymocyte globulin formulations in the prophylaxis of graft-versus-host disease: a systematic review. J Clin Med. 2023;12:5449.

Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009;10:855–64.

Article  CAS  PubMed  Google Scholar 

Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43–53.

Article  PubMed  Google Scholar 

Chang Y-J, Wu D-P, Lai Y-R, Liu Q-F, Sun Y-Q, Hu J, et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study. J Clin Oncol. 2020;38:3367–76.

Article  CAS  PubMed  Google Scholar 

Cho B-S, Min G-J, Park S-S, Yoon SY, Park S, Jeon Y-W, et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. Am J Hematol. 2021;96:1441–9.

Article  CAS  PubMed  Google Scholar 

Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: Final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematol. 2019;6:e89–e99.

Article  PubMed  Google Scholar 

Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017;35:4003–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. The Lancet. Oncology. 2016;17:164–73.

CAS  PubMed  Google Scholar 

Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703–8.

Article  CAS  PubMed  Google Scholar 

Battipaglia G, Ruggeri A, Labopin M, Volin L, Blaise D, Socié G, et al. Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. Bone Marrow Transpl. 2018;53:1295–303.

Article  CAS  Google Scholar 

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825–8.

CAS  Google Scholar 

Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56.

Article  Google Scholar 

Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, et al. Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. Haematologica. 2019;104:1230–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samuelson Bannow BT, Salit RB, Storer BE, Stevens EA, Wu D, Yeung C, et al. Hematopoietic cell transplantation for myelofibrosis: the dynamic international prognostic scoring system plus risk predicts post-transplant outcomes. Soc Blood Marrow Transpl. 2018;24:386–92.

Article  Google Scholar 

Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone marrow Transpl. 2014;49:389–96.

Article  CAS  Google Scholar 

Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117:6963–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, et al. Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. Br J Haematol 2018;182:418–22.

Article  PubMed  Google Scholar 

McLornan DP, Hernandez-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: Proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia. 2021;35:2445–59.

Article  PubMed  Google Scholar 

Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, et al. Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation. Bone Marrow Transpl. 2024;59:550–7.

Gagelmann N, Salit RB, Schroeder T, Badbaran A, Rautenberg C, Panagiota V, et al. High molecular and cytogenetic risk in myelofibrosis does not benefit from higher intensity conditioning before hematopoietic cell transplantation: an international collaborative analysis. HemaSphere. 2022;6:e784.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, et al. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the chronic malignancies working party of the European Society for Blood and Marrow Transplantation. Soc Blood Marrow Transpl. 2019;25:2167–71.

Article  Google Scholar 

Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, et al. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023;108:1900–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133:2233–42.

Article  CAS  PubMed  Google Scholar 

Gupta V, Malone AK, Hari PN, Ahn KW, Hu Z-H, Gale RP, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: A cohort analysis from the center for international blood and marrow transplant research. J Am Soc Blood Marrow Transpl. 2014;20:89–97.

Article  Google Scholar 

Raj K, Eikema D-J, McLornan DP, Olavarria E, Blok H-J, Bregante S, et al. Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the chronic malignancies working party of European Society for Blood and Marrow Transplantation. Soc Blood Marrow Transpl. 2019;25:522–8.

Article  Google Scholar 

Gambella M, Bregante S, Raiola AM, Varaldo R, Ghiso A, Schiavetti I, et al. Haploidentical hematopoietic cell transplantation for myelofibrosis in the ruxolitinib era. Transplant Cell Ther 2023;29:49.e1–49.e7.

Article  CAS  PubMed  Google Scholar 

Kröger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, et al. Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation. Am Soc Blood Marrow Transpl. 2018;24:2152–6.

Article  Google Scholar 

Ali H, Tsai N-C, Synold T, Mokhtari S, Tsia W, Palmer J, et al. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: A pilot open-label study. Blood Adv. 2022;6:1444–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salit RB, Scott BL, Stevens EA, Baker KK, Gooley TA, Deeg HJ. Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis. Bone Marrow Transpl. 2020;55:70–76.

Article  CAS  Google Scholar 

Kennedy VE, Chen H, Savani BN, Greer J, Kassim AA, Engelhardt BG, et al. Optimizing antithymocyte globulin dosing for unrelated donor allogeneic hematopoietic cell transplantation based on recipient absolute lymphocyte count. Soc Blood Marrow Transpl. 2018;24:150–5.

Article  CAS 

留言 (0)

沒有登入
gif